

FOR IMMEDIATE RELEASE

Company Name Kyowa Kirin Co., Ltd.
Representative Abdul Mullick, President and COO
(Code No. 4151, TSE Prime)
Inquiries Hiroki Nakamura, Executive Vice President,
Corporate Communications Department
Media Contact: +81-3-5205-7205
Investor Contact: +81-3-5205-7206

(Correction) "Appendix to the Consolidated Financial Summary Fiscal 2025"

Tokyo, Japan, February 27, 2026 – Kyowa Kirin Co., Ltd. (hereinafter "Kyowa Kirin") hereby announces that the following corrections have been made to certain information in the "Appendix to the Consolidated Financial Summary Fiscal 2025" announced on February 9, 2026.

1. Reason for Corrections

This is to correct the errors on the following pages of the "Appendix to the Consolidated Financial Summary Fiscal 2025".

- Page 2 : Consolidated Financial Results
- Page 3 : Capital expenditures and intangible assets investment, depreciation and amortization
- Page 4 : Revenue by Products

2. Details of Corrections

Corrections are underlined in red from the next page.

END

1. Consolidated Financial Results

【Before Correction】

I. Consolidated Financial Results

2. Trends in consolidated profit (Based on the newly defined Core Operating Profit)

<Accumulative - New Core Base>

	FY 2024 results				FY 2025 results				FY 2026 forecasts			
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Rate of change	Jan - Dec	Rate of change
Revenue	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	0%	520.0	5%
Cost of sales	(25.6)	(59.5)	(94.0)	(132.6)	(24.6)	(61.9)	(90.1)	(127.9)	4.7	(4)%	(129.0)	1%
Gross profit	80.0	173.5	268.8	362.9	80.1	168.8	259.4	368.9	5.9	2%	391.0	6%
<i>Gross profit to revenue ratio</i>	75.8%	74.5%	74.1%	73.2%	76.5%	73.2%	74.2%	74.2%	-	-	75.2%	-
Selling, general and administrative expenses ²	(38.8)	(79.7)	(117.7)	(160.0)	(40.4)	(79.5)	(116.5)	(157.9)	2.1	(1)%	(169.0)	7%
Research and development expenses	(23.3)	(49.2)	(74.3)	(103.5)	(28.6)	(52.5)	(76.8)	(101.2)	2.4	(2)%	(122.0)	21%
★ <i>R&D expense ratio</i>	22.1%	21.1%	20.5%	20.9%	27.3%	22.8%	22.0%	20.4%	-	-	23.5%	-
Core operating profit	17.9	44.5	76.8	99.4	11.2	36.8	66.1	109.8	10.4	10%	100.0	(9)%
★ <i>Core operating profit ratio</i>	16.9%	19.1%	21.2%	20.1%	10.7%	16.0%	18.9%	22.1%	-	-	19.2%	-
Amortization (intangible assets) ³	(1.4)	(3.5)	(6.0)	(7.6)	(1.7)	(3.4)	(5.1)	(7.6)	0.0	(0)%	(11.0)	45%
Share of profit (loss) of investments accounted for using equity method	0.9	3.1	3.5	3.5	(0.9)	1.5	1.0	0.8	(2.8)	(78)%	(2.0)	-
Other income	2.6	4.4	13.3	13.1	0.4	0.6	0.7	1.1	(12.0)	(92)%		
Other expenses	(2.8)	(4.7)	(16.9)	(19.3)	(1.6)	(12.9)	(14.7)	(18.0)	1.3	(7)%		
Finance income (costs)	0.8	2.6	0.8	(5.8)	0.4	(0.7)	(0.1)	1.1	6.8	-		
Profit before tax	18.1	46.5	71.6	83.5	7.9	22.0	47.9	87.2	3.8	5%	95.0	9%
Income tax expense	(3.5)	(8.7)	(15.7)	(23.6)	(1.7)	(5.7)	(15.3)	(20.2)	3.4	(14)%	(20.0)	(1)%
<i>Ratio of income tax burden</i>	19.2%	18.8%	21.9%	28.3%	21.5%	25.7%	32.0%	23.1%	-	-	-	-
Profit	14.6	37.8	55.9	59.9	6.2	16.3	32.6	67.0	7.2	12%	75.0	12%
<i>Profit to revenue ratio</i>	13.9%	16.2%	15.4%	12.1%	5.9%	7.1%	9.3%	13.5%	-	-	14.4%	-

Unit: Billions of yen

FY 2028 forecasts

Early 20% range

7% or higher
Progressive payout of 4% or more

ROE(%) 7.1 7.7 0.6 8.2
 ★ROE(%) ※ Three-year average 8.2 8.3 0.1 7.7
 ★DOE(%)⁴ 3.6 3.8 0.2 4.1

【After Correction】

I. Consolidated Financial Results

2. Trends in consolidated profit (Based on the newly defined Core Operating Profit)

<Accumulative - New Core Base>

	FY 2024 results				FY 2025 results				FY 2026 forecasts			
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Rate of change	Jan - Dec	Rate of change
Revenue	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	0%	520.0	5%
Cost of sales	(25.6)	(59.5)	(94.0)	(132.6)	(24.6)	(61.9)	(90.1)	(127.9)	4.7	(4)%	(129.0)	1%
Gross profit	80.0	173.5	268.8	362.9	80.1	168.8	259.4	368.9	5.9	2%	391.0	6%
<i>Gross profit to revenue ratio</i>	75.8%	74.5%	74.1%	73.2%	76.5%	73.2%	74.2%	74.2%	-	-	75.2%	-
Selling, general and administrative expenses ²	(38.8)	(79.7)	(117.7)	(160.0)	(40.4)	(79.5)	(116.5)	(157.9)	2.1	(1)%	(169.0)	7%
Research and development expenses	(23.3)	(49.2)	(74.3)	(103.5)	(28.6)	(52.5)	(76.8)	(101.2)	2.4	(2)%	(122.0)	21%
★ <i>R&D expense ratio</i>	22.1%	21.1%	20.5%	20.9%	27.3%	22.8%	22.0%	20.4%	-	-	23.5%	-
Core operating profit	17.9	44.5	76.8	99.4	11.2	36.8	66.1	109.8	10.4	10%	100.0	(9)%
★ <i>Core operating profit ratio</i>	16.9%	19.1%	21.2%	20.1%	10.7%	16.0%	18.9%	22.1%	-	-	19.2%	-
Amortization (intangible assets) ³	(1.4)	(3.5)	(6.0)	(7.6)	(1.7)	(3.4)	(5.1)	(7.6)	0.0	(0)%	(11.0)	45%
Share of profit (loss) of investments accounted for using equity method	0.9	3.1	3.5	3.5	(0.9)	1.5	1.0	0.8	(2.8)	(78)%	(2.0)	-
Other income	2.6	4.4	13.3	13.1	0.4	0.6	0.7	1.1	(12.0)	(92)%		
Other expenses	(2.8)	(4.7)	(16.9)	(19.3)	(1.6)	(12.9)	(14.7)	(18.0)	1.3	(7)%		
Finance income (costs)	0.8	2.6	0.8	(5.8)	0.4	(0.7)	(0.1)	1.1	6.8	-		
Profit before tax	18.1	46.5	71.6	83.5	7.9	22.0	47.9	87.2	3.8	5%	95.0	9%
Income tax expense	(3.5)	(8.7)	(15.7)	(23.6)	(1.7)	(5.7)	(15.3)	(20.2)	3.4	(14)%	(20.0)	(1)%
<i>Ratio of income tax burden</i>	19.2%	18.8%	21.9%	28.3%	21.5%	25.7%	32.0%	23.1%	-	-	-	-
Profit	14.6	37.8	55.9	59.9	6.2	16.3	32.6	67.0	7.2	12%	75.0	12%
<i>Profit to revenue ratio</i>	13.9%	16.2%	15.4%	12.1%	5.9%	7.1%	9.3%	13.5%	-	-	14.4%	-

Unit: Billions of yen

FY 2028 forecasts

Early 20% range

Mid 7% range
Progressive payout of 4% or more

ROE(%) 7.1 7.7 0.6 8.2
 ★ROE(%) ※ Three-year average 8.2 8.3 0.1 7.7
 ★DOE(%)⁴ 3.6 3.8 0.2 4.1

Page 3 of the "Appendix to the Consolidated Financial Summary Fiscal 2025 "
 Capital expenditures and intangible assets investment, depreciation and amortization

【Before Correction】

4. Capital expenditures and intangible assets investment, depreciation and amortization

Unit: Billions of yen

	FY 2024 results				FY 2025 results				FY 2026 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Capital expenditures (property, plant and equipment) ¹	4.9	12.3	19.0	29.5	8.2	14.9	22.9	35.0	33.9
Intangible assets investment	17.7	21.9	25.5	79.3	1.3	9.9	21.3	48.1	18.3
Total	22.5	34.2	44.6	108.7	9.4	24.9	44.2	83.1	52.2
Depreciation (property, plant and equipment)	3.7	7.4	11.0	14.8	3.8	7.6	11.7	15.8	16.8
Amortization (intangible assets)	2.0	4.7	7.8	10.0	2.3	4.7	7.1	10.4	15.0
Of which, sales right ²	1.4	3.5	6.0	7.6	1.7	3.4	5.1	7.6	11.1
Total	5.6	12.1	18.8	24.8	6.1	12.3	18.8	26.1	31.7

*1 Acquisitions of right-of-use assets are not included.

*2 From 2026 onward, amortization of intangible assets will be presented as a separate line item in the consolidated statement of profit or loss.

【After Correction】

4. Capital expenditures and intangible assets investment, depreciation and amortization

Unit: Billions of yen

	FY 2024 results				FY 2025 results				FY 2026 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Capital expenditures (property, plant and equipment) ¹	4.9	12.3	19.0	29.5	8.2	14.9	22.9	35.0	33.9
Intangible assets investment	17.7	21.9	25.5	79.3	1.3	9.9	21.3	48.1	18.3
Total	22.5	34.2	44.6	108.7	9.4	24.9	44.2	83.1	52.2
Depreciation (property, plant and equipment)	3.7	7.4	11.0	14.8	3.8	7.6	11.7	15.8	16.8
Amortization (intangible assets)	2.0	4.7	7.8	10.0	2.3	4.7	7.1	10.4	15.0
Of which, sales right ²	1.4	3.5	6.0	7.6	1.7	3.4	5.1	7.6	11.0
Total	5.6	12.1	18.8	24.8	6.1	12.3	18.8	26.1	31.7

*1 Acquisitions of right-of-use assets are not included.

*2 From 2026 onward, amortization of intangible assets will be presented as a separate line item in the consolidated statement of profit or loss.

Page 4 of the "Appendix to the Consolidated Financial Summary Fiscal 2025 "
Revenue by Products

【Before Correction】

III. Status of Main Products
1. Revenue by Products

<Accumulative> Unit: Billions of yen

	FY 2024 results				FY 2025 results							FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec latest forecasts	% of forecasts	Jan - Dec	Rate of change
Products ¹¹	93.4	208.7	327.9	446.8	91.8	205.2	310.1	438.4	(8.4)	425.7	103%	445.1	2%
Crysvita	37.8	90.9	134.9	196.6	42.4	99.8	146.7	216.4	19.8	210.2	103%	235.4	9%
Poteligeo	8.6	19.1	29.1	39.9	9.8	21.6	33.7	45.7	5.8	45.4	101%	54.6	20%
Libmeldy/Lenmeldy	1.1	1.4	2.2	3.3	2.1	4.4	4.4	6.4	3.2	6.9	94%	10.0	56%
Nourianz	1.6	3.5	6.2	8.8	2.0	4.6	6.9	9.5	0.7	8.2	116%	7.4	(22)%
PHOZEVEL	0.6	1.7	2.9	4.7	1.5	3.7	5.9	8.2	3.6	8.9	92%	11.6	41%
Duvroq	2.5	5.7	8.9	12.7	3.0	6.9	10.9	15.5	2.8	15.5	100%	16.2	5%
Nesp	0.7	1.4	2.0	2.6	0.5	0.9	1.1	1.4	(1.3)	2.0	71%	0.8	(41)%
Darbepoetin Alfa Injection Syringe [KKF]	2.8	5.6	8.5	11.6	2.3	4.9	7.6	10.4	(1.1)	9.6	109%	9.2	(12)%
G-Lasta	5.8	10.5	15.3	20.5	4.3	9.1	13.7	18.2	(2.4)	17.0	107%	16.2	(11)%
Romiplate	3.0	6.5	9.9	13.9	3.4	7.3	11.5	15.9	2.0	14.6	109%	11.4	(28)%
Orkedia	2.2	4.9	7.5	10.4	2.4	5.4	8.2	11.3	0.9	10.7	106%	11.6	3%
Rituximab BS [KHK]	1.9	3.8	5.7	7.8	1.5	3.2	5.0	6.9	(1.0)	6.0	114%	7.9	16%
Nourias	1.5	3.4	5.1	6.9	1.4	3.1	4.6	6.3	(0.6)	6.5	97%	5.1	(19)%
HARUROPI	1.0	2.2	3.3	4.6	1.0	2.1	3.3	4.5	(0.0)	4.8	95%	4.0	(12)%
Dovobet ¹²	1.8	3.9	5.8	7.9	-	-	-	-	(7.9)	-	-	-	-
Technology out-licensing ¹³	12.1	24.3	34.9	48.8	13.0	25.5	39.4	58.4	9.7	52.3	112%	74.9	28%
Benralizumab royalty ¹⁴	6.4	14.4	21.6	31.4	7.4	15.7	25.4	38.1	6.7	-	-	-	-
Total	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	478.0		520.0	

【After Correction】

III. Status of Main Products
1. Revenue by Products

<Accumulative> Unit: Billions of yen

	FY 2024 results				FY 2025 results							FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec latest forecasts	% of forecasts	Jan - Dec	Rate of change
Products ¹¹	93.4	208.7	327.9	446.8	91.8	205.2	310.1	438.4	(8.4)	425.7	103%	445.1	2%
Crysvita	37.8	90.9	134.9	196.6	42.4	99.8	146.7	216.4	19.8	210.2	103%	235.4	9%
Poteligeo	8.6	19.1	29.1	39.9	9.8	21.6	33.7	45.7	5.8	45.4	101%	54.6	20%
Libmeldy/Lenmeldy	1.1	1.4	2.2	3.3	2.1	4.4	4.4	6.4	3.2	6.9	94%	10.0	56%
Nourianz	1.6	3.5	6.2	8.8	2.0	4.6	6.9	9.5	0.7	8.2	116%	7.4	(22)%
PHOZEVEL	0.6	1.7	2.9	4.7	1.5	3.7	5.9	8.2	3.6	8.9	92%	11.6	41%
Duvroq	2.5	5.7	8.9	12.7	3.0	6.9	10.9	15.5	2.8	15.5	100%	16.2	5%
Nesp	0.7	1.4	2.0	2.6	0.5	0.9	1.1	1.4	(1.3)	2.0	71%	0.8	(41)%
Darbepoetin Alfa Injection Syringe [KKF]	2.8	5.6	8.5	11.6	2.3	4.9	7.6	10.4	(1.1)	9.6	109%	9.2	(12)%
G-Lasta	5.8	10.5	15.3	20.5	4.3	9.1	13.7	18.2	(2.4)	17.0	107%	16.2	(11)%
Romiplate	3.0	6.5	9.9	13.9	3.4	7.3	11.5	15.9	2.0	14.6	109%	11.4	(28)%
Orkedia	2.2	4.9	7.5	10.4	2.4	5.4	8.2	11.3	0.9	10.7	106%	11.6	3%
Rituximab BS [KHK]	1.9	3.8	5.7	7.8	1.5	3.2	5.0	6.9	(1.0)	6.0	114%	5.7	(18)%
Nourias	1.5	3.4	5.1	6.9	1.4	3.1	4.6	6.3	(0.6)	6.5	97%	5.1	(19)%
HARUROPI	1.0	2.2	3.3	4.6	1.0	2.1	3.3	4.5	(0.0)	4.8	95%	4.0	(12)%
Dovobet ¹²	1.8	3.9	5.8	7.9	-	-	-	-	(7.9)	-	-	-	-
Technology out-licensing ¹³	12.1	24.3	34.9	48.8	13.0	25.5	39.4	58.4	9.7	52.3	112%	74.9	28%
Benralizumab royalty ¹⁴	6.4	14.4	21.6	31.4	7.4	15.7	25.4	38.1	6.7	-	-	-	-
Total	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	478.0		520.0	